Yves here. $500 million, for somewhat disfavored vaccine approach (because seizures, among other reasons), for a flu vaccine safety tested on only 45 people? This sounds like the medical industry version of vaporware. But why should HHS be any more pure than the rest of the Trump Administration by forswearing grifting?

Having said that, there is reason to think inactivated virus vaccines can provide broader immunity; that’s claimed to be true for the oft-maligned Sinovac (China) Covid vaccines.

And even though the flu, particularly in bad years, does kill people, it does not seem all that high on the list of public health risks, if nothing else by not being primed to turn into a full bore crisis, unlike, say, drug-resistant TB. In other words, even if this old vaccine approach does have merit, does it merit this level of priority?

By Arthur Allen, senior KFF Health News correspondent,

Keep reading this article on Naked Capitalism (Yves Smith) - Blog.

Leave a Reply